Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Novavax, with a price target of $6.00. T...

Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX)

Shares of major COVID-19 vaccine makers, Moderna ($MRNA), BioNTech ($BNTX), and Novavax ($NVAX) fell 6%, 5%, and 4%, respectively, on Monday. The d...

Current Quarter	$-0.66	Next Quarter	$-0.35
Current Year	$2.51	Next Year	$-0.37
QoQ Growth	+47.0%	YoY Growth	-114.7%
3Y EPS CAGR	+62.6%	Target Price	$12.67
Consensus	Buy	Upside	+92.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVAX	$6.57	-1.79%	2.92M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVAX	$6.57	-1.8%	2.92M
3
4
5
6

NVAX

NVAX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Novavax Inc. Data in Excel

Get Novavax Inc. Data in Excel